AYŞEGÜL ORUÇ
(Uludağ Üniversitesi, Tıp Fakültesi, Nefroloji Bilim Dalı, Bursa, Türkiye)
ABDULMECİT YILDIZ
(Uludağ Üniversitesi, Tıp Fakültesi, Nefroloji Bilim Dalı, Bursa, Türkiye)
Ebru AÇIKGÖZ
(Zübeyde Hanım Kadın Doğum Hastanesi, Biyokimya Bölümü, Bursa, Türkiye)
MUSTAFA GÜLLÜLÜ
(Zübeyde Hanım Kadın Doğum Hastanesi, Biyokimya Bölümü, Bursa, Türkiye)
Yıl: 2018Cilt: 27Sayı: 1ISSN: 1300-7718Sayfa Aralığı: 26 - 31İngilizce

52 0
Evaluation of Oxidative Stress in Primary Glomerulonephritis with Serum Level of Ischemia Modified Albumin (IMA)
OBJECTIVE: Oxidative stress (OS) is described as the imbalance of oxidative and anti-oxidative systems towards oxidants and plays a role in the pathogenesis of GN. In many studies, ischemiamodified albumin (IMA) is identified as a sign of OS. However, it has not yet been studied in patients with primary GN in the literature. In the present study, we aimed to determine the role of IMA in the pathogenesis of primary GN. MATERIAL and METHODS: Forty-five primary GN patients were divided into two groups as proliferative GN (PGN) (n= 17, 37.8%) and non-proliferative GN (NPGN) (n= 28, 62.2%) according to the histopathological findings. IMA was studied by the cobalt binding method. Since serum albumin levels are commonly low in patients with GN, we calculated the adjusted IMA (aIMA) according to serum albumin. RESULTS: There was no significant difference between the two groups regarding IMA compared with controls (n= 50). IMA was significantly higher in the PGN group compared with the control and NPGN groups (p= 0.009, 0.037; respectively). There was a negative correlation between serum albumin concentration and IMA. CONCLUSION: These results support the role of OS in the pathogenesis of PGN in which inflammatory immune glomerular injury is predominant
Fen > Tıp > Cerrahi
DergiAraştırma MakalesiErişime Açık
  • 1. Mathieson PW: Glomerulonephritis. Semin Immunopathol 2007;29:315-316
  • 2. Chadban SJ, Atkins RC: Glomerulonephritis. Lancet 2005;365: 1797-1806
  • 3. Markan S, Kohli HS, Sud K, Ahuja M, Ahluwalia TS, Sakhuja V, Khullar M: Oxidative stress in primary glomerular diseases: A comparative study. Mol Cell Biochem 2008;311:105-110
  • 4. Gwinner W, Gröne H: Role of reactive oxygen species in glomerulonephritis. Nephrol Dial Transplant 2000;15:1127-1132
  • 5. Halliwell B: Oxidants and human disease: Some new concepts. FASEB J 1987;1:358-364
  • 6. Cerutti PA, Trump BF: Inflammation and oxidative stress in carcinogenesis. Cancer Cells 1991;3:1-7
  • 7. Freeman BA, Crapo JD: Biology of disease: Free radicals and tissue injury. Lab Invest 1982;47:412-426
  • 8. Shah SV: Role of reactive oxygen metabolites in experimental glomerular disease. Kidney Int 1989;35:1093-1106
  • 9. Johnson RJ, Lovett D, Lehrer RI, Couser WG, Klebanoff SJ: Role of oxidants and proteases in glomerular injury. Kidney Int 1994;45:352-359
  • 10. Bülbül M, Oner A, Demircin G, Erdoğan O: Oxidative stress in children with acute glomerulonephritis. Ren Fail 2009;30:209-214
  • 11. Chen Y, Schieppati A, Cai G, Chen X, Zamora J, Giuliano GA, Braun N, Perna A: Immunosuppression for membranous nephropathy: A systematic review and meta-analysis of 36 clinical trials. Clin J Am Soc Nephrol 2013;8:787-796
  • 12. Kuo HT, Kuo MC, Chiu YW, Chang JM, Guh JY, Chen HC: Increased glomerular and extracellular malondialdehyde levels in patients and rats with focal segmental glomerulosclerosis. Eur J Clin Invest 2005;35:245-250
  • 13. Gaertner S, Janssen U, Ostendorf T, Koch KM, Floege J, Gwinner W: Glomerular oxidative and antioxidative systems in experimental mesangioproliferative glomerulonephritis. J Am Soc Nephrol 2002;13:2930-2937
  • 14. Binder C, Weiher H, Exner M, Kerjaschki D: Glomerular overproduction of oxygen radicals in Mpv17 gene-inactivated mice causes podocyte foot process flattening and proteinuria: A model of steroid-resistant nephrosis sensitive to radical scavenger therapy. Am J Pathol 1999;154:1067-1075
  • 15. Bulucu F, Vural A, Aydin A, Sayal A: Oxidative stress status in adults with nephrotic syndrome. Clin Nephrol 2000;53:169-173
  • 16. Túri S, Németh I, Torkos A, Sághy L, Varga I, Matkovics B, Nagy J: Oxidative stress and antioxidant defense mechanism in glomerular diseases. Free Radic Biol Med 1997;22:161-168
  • 17. Lippi G, Montagnana M, Guidi G: Albumin cobalt binding and ischemia modified albumin generation: An endogenous response to ischemia? Int J Cardiol 2006;108:410-411
  • 18. Roy D, Quiles J, Gaze DC, Collinson P, Kaski JC, Baxter GF: Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin. Heart 2006;92:113-114
  • 19. Duarte MM, Rocha JB, Moresco RN, Duarte T, Da Cruz IB, Loro VL, Schetinger MR: Association between ischemia-modified albumin, lipids and inflammation biomarkers in patients with hypercholesterolemia. Clin Biochem 2009;42:666-671
  • 20. Awadallah S, Atoum M, Nimer N, Saleh S: Ischemia modified albumin: An oxidative stress marker in β-thalassemia major. Clin Chim Acta 2012;413:907-910
  • 21. Piva SJ, Duarte MM, Da Cruz IB, Coelho AC, Moreira AP, Tonello R, Garcia SC, Moresco RN: Ischemia-modified albumin as an oxidative stress biomarker in obesity. Clin Biochem 2011;44:345- 347
  • 22. Kurban S, Mehmetoglu I, Yerlikaya H, Gönen S, Erdem S: Effect of chronic regular exercise on serum ischemia-modified albumin levels and oxidative stress in type 2 diabetes mellitus. Endocr Res 2011;36:116-123
  • 23. Kazanis K, Dalamaga M, Kassi E, Nounopoulos C, Manolis AS, Merantzi G, Jullien G, Dionyssiou-Asteriou A: Serum levels of ischemia modified albumin in overweight/obese postmenopausal women: A potential biomarker of atherosclerotic burden associated with oxidative stress. Maturitas 2011;70:182-187
  • 24. Aran T, Unsal M, Guven S, Kart C, Cetin E, Alver A: Carbon dioxide pneumoperitoneum induces systemic oxidative stress: A clinical study. Eur J Obstet Gynecol Reprod Biol 2012;161:80-83
  • 25. Valle Gottlieb MG, da Cruz IB, Duarte MM, Moresco RN, Wiehe M, Schwanke CH, Bodanese LC: Associations among metabolic syndrome, ischemia, inflammatory, oxidatives, and lipids biomarkers. J Clin Endocrinol Metab 2010;95:586-591
  • 26. Işik S, Kılıç S, Öğretmen Z, Çakır DÜ, Türkön H, Cevizci S, Hız MM: The correlation between the psoriasis area severity index and ischemia-modified albumin, mean platelet volume levels in patients with psoriasis. Postepy Dermatol Alergol 2016;33:290-293
  • 27. Bar-Or D, Lau E, Winkler JV: A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med 2000;19:311-315
  • 28. Gaze D, Crompton L, Collinson P: Ischemia-modified albumin concentrations should be interpreted with caution in patients with low serum albumin concentrations. Med Princ Pract 2006;15:322- 324
  • 29. Lee YW, Kim HJ, Cho YH, Shin H, Choi TY, Lee YK: Application of albumin-adjusted ischemia modified albumin index as an early screening marker for acute coronary syndrome. Clin Chim Acta 2007;384:24-27
  • 30. Lippi G, Montagnana M, Salvagno GL, Guidi GC: Standardization of ischemia-modified albumin testing: Adjustment for serum albumin. Clin Chem Lab Med 2007;45:261-262
  • 31. Araujo M, Welch WJ: Oxidative stress and nitric oxide in kidney function. Curr Opin Nephrol Hypertens 2006;15:72-77
  • 32. Wójcicka G, Bełtowski J: Oxidative stress in glomerulonephritis. Postepy Hig Med Dosw 2001;55:855-869
  • 33. Tipping PG: Are podocytes passive or provocative in proteinuric glomerular pathology? J Am Soc Nephrol 2008;19:651-653
  • 34. Shah S: Oxidants in progressive kidney disease. In: Alpern RJ, Moe OW, Caplan M (eds), The Kidney: Physiology and Pathophysiology. USA: Elsevier, 2008;2601-2613
  • 35. Baud L, Fouqueray B, Philippe C, Ardaillou R: Reactive oxygen species as glomerular autacoids. J Am Soc Nephrol 1992;2:S132- 138
  • 36. Fantone JC, Ward PA: Role of oxygen-derived free radicals and metabolites in leukocyte-dependent inflammatory reactions. Am J Pathol 1982;107:395-418
  • 37. Montagnana M, Lippi G, Tessitore N, Salvagno GL, Targher G, Gelati M, Lupo A, Guidi GC: Effect of hemodialysis on traditional and innovative cardiac markers. J Clin Lab Anal 2008;22:59-65
  • 38. Kiyici A, Mehmetoğlu I, Karaoğlan H, Atalay H, Solak Y, Türk S: Ischemia-modified albumin levels in patients with end-stage renal disease patients on hemodialysis: Does albumin analysis method affect albumin-adjusted ischemia-modified albumin levels? J Clin Lab Anal 2010;24:273-277
  • 39. Carrega L, Giaime P, Montserrat C, Vincente O, Brunet P, Dussol B, Berland Y, Guieu R: Influence of the dialysis membrane on markers of tissue ischemia. J Investig Med 2006;54:62-66
  • 40. Cichota LC, Moresco RN, Duarte MM, da Silva JE: Evaluation of ischemia modified albumin in anemia associated to chronic kidney disease. J Clin Lab Anal 2008;22:1-5
  • 41. Sayar E, Özdem S, Uzun G, İşlek A, Yılmaz A, Artan R: Total oxidant status, total antioxidant capacity and ischemia modified albumin levels in children with celiac disease. Turk J Pediatr 2015;57:498-503
  • 42. Beyazit F, Yilmaz N, Balci O, Adam M, Yaman ST: Evaluation of oxidative stress in women with polycystic ovarian syndrome as represented by serum ischemia modified albumin and its correlation with testosterone and insulin resistance. Inter Med 2016;55:2359- 2364
  • 43. Ahmad A, Manjrekar P, Yadav C, Agarwal A, Srikantiah R, Hegde A: Evaluation of ischemia-modified albumin, malondialdehyde, and advanced oxidative protein products as markers of vascular injury in diabetic nephropathy. Biomark Insights 2016;11:63-68
  • 44. Piwowar A, Knapik-Kordecka M, Warwas M: Ischemia-modified albumin level in type 2 diabetes mellitus - Preliminary report. Dis Markers 2008;24:311-317

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.